The repeated failure of clinical trials targeting the amyloid beta (Aβ) protein has challenged the amyloid cascade hypothesis. In this perspective, I discuss the biogenesis and biology of Aβ, from the arrangement of its atoms to its effects on the human brain. I hope that this analysis will help guide future attempts to home in on this elusive therapeutic target.
|Original language||English (US)|
|Number of pages||7|
|Journal||Alzheimer's and Dementia|
|State||Published - Nov 2020|
Bibliographical noteFunding Information:
I thank David Knopman and Rob Tycko for provocative discussions and insightful comments about this manuscript, and Peng Liu for his vital contributions to the delineation and characterization of type 1 and type 2 oligomers in the brain. Funding: NIH R01-NS/AG33249, B. Grossman, T. and P. Grossman Family Foundation.
© 2020 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association